AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Vaccines & Immune Therapies / Infectious Disease by Year
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) ($M)
AstraZeneca Vaccines & Immune Therapies / Infectious Disease: $846M in FY2025, down 20.0% from a year earlier.
Where the FY2025 figure comes from
“|| V&I | 846 | (20) | (20) | 209 | (26) | 220 | 3 | 5 | 354 | (13) | (15) | 63 | (60) | (60)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Therapy Area & Region Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 846 | -20.0% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 1,058 | +4.5% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 1,012 | -78.6% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 4,736 | – | Form 6-K FY2022Q4 Earnings Release ↗ |
Breakdown
What makes up vaccines & Immune Therapies / Infectious Disease
- Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide YoY actual (%)-20.0% · FY2025
- Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide YoY CER (%)-20.0% · FY2025
- Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — US product sales ($M)209 · FY2025
- Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets product sales ($M)220 · FY2025
- Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Europe product sales ($M)354 · FY2025
- Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW product sales ($M)63 · FY2025
- Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M)281 · FY2025
- FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M)272 · FY2025
- Other Vaccines & Immune Therapies — Worldwide product sales ($M)1 · FY2025
- Synagis (palivizumab) — Worldwide product sales ($M)292 · FY2025
Cite this data
StockData. (2026). AstraZeneca Vaccines & Immune Therapies / Infectious Disease ($M), annual FY2022–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta-vi-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.